TY - JOUR
T1 - Trabectedin in advanced uterine leiomyosarcomas
T2 - A retrospective case series analysis from two reference centers
AU - Sanfilippo, Roberta
AU - Grosso, Federica
AU - Jones, Robin L.
AU - Banerjee, Susana
AU - Pilotti, Silvana
AU - D'Incalci, Maurizio
AU - Tos, Angelo Paolo Dei
AU - Raspagliesi, Francesco
AU - Judson, Ian
AU - Casali, Paolo Giovanni
PY - 2011/12
Y1 - 2011/12
N2 - Background: Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. Patients and methods: A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed. Results: Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively. Conclusions: Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.
AB - Background: Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma. Patients and methods: A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed. Results: Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively. Conclusions: Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.
KW - Chemotherapy
KW - Leiomyosarcoma
KW - Soft tissue sarcoma
KW - Trabectedin
KW - Uterine neoplasms
UR - http://www.scopus.com/inward/record.url?scp=81155149886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81155149886&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2011.08.016
DO - 10.1016/j.ygyno.2011.08.016
M3 - Article
C2 - 21917307
AN - SCOPUS:81155149886
VL - 123
SP - 553
EP - 556
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -